STOCK TITAN
  1. Home
  2. News
  3. TARO

Taro Pharmaceutical Industries - TARO STOCK NEWS

Welcome to our dedicated news page for Taro Pharmaceutical Industries (Ticker: TARO), a resource for investors and traders seeking the latest updates and insights on Taro Pharmaceutical Industries.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Taro Pharmaceutical Industries's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Taro Pharmaceutical Industries's position in the market.

News
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Rhea-AI Summary
Taro Pharmaceutical Industries announces an Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for the approval of a merger with Sun Pharmaceutical Industries The merger involves Taro merging with Libra Merger , a company under Sun Pharma's control, and becoming a subsidiary of Sun Pharma. Shareholders will vote on the merger, which has been recommended by independent committees and the Board. If approved, Taro will become a privately held company, delisting from the NYSE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
acquisition
-
News
Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
Rhea-AI Summary
Krensavage Asset Management remains opposed to Sun Pharmaceutical Industries Ltd.'s bid to take Taro Pharmaceutical Industries Ltd. private, citing the inadequate offer that undervalues Taro's assets and cash generation. The bid is seen as a 9% discount to the value of Taro's tangible assets, with concerns raised about the special committee's responsibility in neglecting Taro's value and its ability to generate cash. Sun's offer is also criticized for being lower than Taro's stock repurchase price in 2019. Krensavage Asset Management, as the second-largest Taro shareholder, continues to decline support for the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
News
Taro Provides Results for December 31, 2023
Rhea-AI Summary
Taro Pharmaceutical Industries Ltd. (TARO) reported unaudited financial results for the quarter and nine months ended December 31, 2023, showing an increase in net sales, gross profit, and operating income compared to the previous year. However, the company also faced increased R&D and SG&A expenses, as well as certain one-time charges. Taro also announced a merger agreement with Sun Pharmaceutical Industries Limited, subject to shareholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
News
Taro to Release Third Quarter Results on January 25, 2024
Rhea-AI Summary
Taro Pharmaceutical Industries Ltd. (TARO) is set to release its financial results for the third quarter ended December 31, 2023, on January 25, 2024. The release will be available on Taro's website, www.taro.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Taro Announces Merger Agreement with Sun Pharma
Rhea-AI Summary
Sun Pharma and Taro Pharmaceutical Industries Ltd. have entered into a definitive merger agreement, with Sun Pharma acquiring all outstanding ordinary shares of Taro for US$43.00 per share, representing a 48% premium over the unaffected price on May 25, 2023. The merger is expected to close in the first half of 2024, and upon completion, Taro will become a privately held company and its shares will no longer be listed on the NYSE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
acquisition
-
News
Taro Provides Results for September 30, 2023
Rhea-AI Summary
Taro Pharmaceutical Industries Ltd. reports unaudited financial results for Q3 and six months ended September 30, 2023. Net sales increased due to a one-time GTN adjustment. Gross profit also increased. R&D expenses and SMG&A expenses increased. Operating income improved. Net income turned positive. Cash flow from operations improved. Cash and cash equivalents increased.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
News
Taro to Release Second Quarter Results on October 26, 2023
Rhea-AI Summary
Taro Pharmaceutical to release Q2 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
earnings
-
News
Taro Provides Results for the Quarter Ended June 30, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
-
News
Taro to Release First Quarter Results on July 26, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
earnings
News
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
Stock TARO logo
Taro Pharmaceutical Industries

NYSE:TARO

TARO Rankings

#2059 Ranked by Market Cap
#1295 Ranked by Stock Gains
N/A Ranked by Dividends

TARO Stock Data

1.58B
8.09M
78.48%
13.45%
0.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
IL
Haifa

About TARO

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.